Litigation Details for Allergan, Inc. v. Lupin Ltd. (E.D. Tex. 2011)

« Back to Dashboard

Allergan, Inc. v. Lupin Ltd. (E.D. Tex. 2011)

Docket		Date Filed	2011-12-30
Court	District Court, E.D. Texas	Date Terminated	2013-11-07
Cause	35:271 Patent Infringement	Assigned To	James Rodney Gilstrap
Jury Demand	Both	Referred To
Parties	FALCON PHARMACEUTICALS, LTD
Patents	8,008,338; 8,207,215; 8,377,982
Attorneys	Kathleen B Barry
Firms	Fish & Richardson - Minneapolis
Link to Docket	External link to docket

Details for Allergan, Inc. v. Lupin Ltd. (E.D. Tex. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-12-30				External link to document

Allergan Inc. v. Lupin Ltd., 2:11-cv-00530: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Allergan, Inc. v. Lupin Ltd., No. 2:11-cv-00530, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Lupin's abbreviated new drug application for a generic ophthalmic bimatoprost product corresponding to Allergan's Lumigan 0.01% ophthalmic solution. The dispute centered on formulation and method-of-treatment patent protection, including U.S. Patent No. 7,851,504. The case was part of Allergan's broader effort to delay generic competition to its glaucoma franchise.

What drug was at issue in Allergan v. Lupin?

The litigation concerned bimatoprost ophthalmic solution, the active ingredient in Lumigan, an Allergan product used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Item	Detail
Brand	Lumigan 0.01%
Active ingredient	Bimatoprost
Dosage form	Ophthalmic solution
Therapeutic category	Prostaglandin analog glaucoma therapy
NDA holder	Allergan
ANDA applicant	Lupin Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 2:11-cv-00530
Primary patent issue	Bimatoprost ophthalmic formulation and related use claims
Principal patent associated with the dispute	U.S. Patent No. 7,851,504

Lumigan 0.01% was designed as a lower-concentration formulation than the earlier Lumigan 0.03% product. Allergan's commercial position depended on maintaining the clinical and patent distinction between the two formulations.

What patents protected Lumigan and bimatoprost ophthalmic solution?

The relevant patent estate included composition, formulation, and treatment patents. The principal patent associated with the later-generation Lumigan 0.01% product was U.S. Patent No. 7,851,504.

U.S. Patent No. 7,851,504

The '504 patent covered ophthalmic compositions containing bimatoprost and related treatment methods. Its importance arose from the formulation's reduced bimatoprost concentration and the effort to preserve intraocular-pressure-lowering efficacy while reducing adverse effects associated with the earlier formulation.

The patent was issued in December 2010. Its term was based on the applicable priority and patent-term rules, with an expiration date in the late 2020s according to Orange Book patent information. The patent was commercially more significant than the original bimatoprost patent because it was directed to the Lumigan 0.01% formulation that became Allergan's principal marketed product.

Earlier bimatoprost patents

Allergan's broader Lumigan estate also included earlier patents relating to bimatoprost, ophthalmic compositions, and glaucoma treatment. Those earlier patents had shorter remaining terms by the time Lupin filed its ANDA.

The litigation value of the older patents was therefore limited compared with the '504 patent. In a Hatch-Waxman case, an earlier patent may still create a 30-month stay and litigation leverage, but a later-expiring formulation patent generally determines the practical generic-entry date.

How did Lupin challenge Allergan's patents?

Lupin's ANDA certification strategy created the basis for the lawsuit under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product.

Allergan's complaint followed Lupin's patent certification and alleged that Lupin's proposed bimatoprost product would infringe the asserted patents. Lupin could respond by arguing that:

1. The asserted claims were invalid for obviousness or lack of patentable subject matter.
2. The proposed generic formulation did not meet one or more claim limitations.
3. The asserted patents were unenforceable if Allergan had engaged in inequitable conduct.
4. The patents did not provide an enforceable barrier to the proposed ANDA product.

The central technical dispute was whether the claimed lower-concentration bimatoprost formulation would have been obvious in view of the earlier Lumigan product, other prostaglandin analogs, and ophthalmic formulation knowledge available before the relevant filing date.

What was the legal significance of the Lumigan formulation patent?

The case illustrates the difference between an active-ingredient patent and a product-specific formulation patent.

An active-ingredient patent protects the molecule itself. A formulation patent can protect a later product containing the same molecule if the formulation provides a patentable technical distinction. For Lumigan 0.01%, the relevant distinction involved the lower concentration of bimatoprost and the resulting formulation and therapeutic characteristics.

The formulation strategy gave Allergan a second period of patent protection after the commercial value of the original bimatoprost protection had declined. That strategy is common in ophthalmology, where small differences in concentration, preservatives, pH, viscosity, dosing frequency, and tolerability can support separate patent claims.

The strength of the estate depended on whether the asserted claims required a specific concentration, excipient profile, or treatment result. Narrow formulation claims can be easier to design around than broad composition claims, but they can still delay an ANDA if the generic product must use substantially the same formulation to obtain approval.

What was the litigation status and outcome?

The case was filed in 2011 in the District of Delaware and proceeded as an ANDA litigation matter. The public record associates the action with Allergan's Lumigan 0.01% patent enforcement program against generic applicants.

The case should be analyzed separately from Allergan's later disputes involving other ophthalmic products, including Combigan and Restasis. Those products involved different active ingredients, patents, regulatory records, and commercial-entry dates.

The docket's significance is primarily strategic: Allergan used the litigation to enforce the late-expiring Lumigan formulation estate against a potential generic entrant. The commercially relevant question was not whether Lupin could manufacture bimatoprost, but whether it could obtain FDA approval for a product sufficiently close to Lumigan 0.01% without infringing Allergan's listed patents.

Public Hatch-Waxman settlements often contain confidential commercial terms. Any launch date, license scope, royalty rate, or authorized-generic arrangement must be taken from the filed settlement documents or a later court order. The case docket alone should not be treated as evidence of a particular Lupin launch date or commercial agreement.

What was the FDA and Orange Book status?

Lumigan was approved by the FDA as an ophthalmic bimatoprost product. The FDA Orange Book listed patents associated with the approved product and provided the regulatory framework for ANDA applicants challenging Allergan's patent rights.[1]

The key regulatory consequences were:

• Lupin's Paragraph IV certification triggered Allergan's patent action.
• The lawsuit created the potential for a statutory 30-month stay of final ANDA approval.
• Final approval depended on the Orange Book-listed patent certifications and any applicable exclusivity.
• Patent expiration, settlement terms, or a court judgment could remove the principal barrier to approval.
• No biosimilar pathway applied because bimatoprost is a small-molecule drug, not a biologic.

The case therefore involved generic-entry risk rather than biosimilar substitution risk.

When did Lumigan lose exclusivity?

Lumigan's exclusivity had several layers:

Exclusivity layer	Commercial relevance
New chemical entity exclusivity	Applied to the original active ingredient, not indefinitely to the later formulation
Earlier bimatoprost patents	Protected the molecule and earlier products for a limited term
Formulation patents	Provided later protection for Lumigan 0.01%
Method-of-use patents	Could restrict particular glaucoma treatment methods
Pediatric exclusivity	Could add six months if granted for qualifying studies
ANDA litigation stay	Could delay approval for up to 30 months after the Paragraph IV notice

The principal commercial barrier was the later-expiring formulation patent rather than the original bimatoprost protection. Generic bimatoprost products eventually entered the U.S. market after the relevant patent barriers weakened or expired, although the timing differed by strength, formulation, applicant, and settlement position.

How strong was Allergan's patent estate?

Allergan's estate was moderately strong from a commercial-delay perspective but more vulnerable from a validity and design-around perspective.

Strengths

• The later formulation patent targeted the commercially important Lumigan 0.01% product.
• Ophthalmic generics must satisfy strict formulation and bioequivalence requirements.
• A generic applicant may need to use a formulation close to the reference product to obtain approval.
• Orange Book listing enabled a Paragraph IV enforcement action and potential approval stay.
• Allergan had experience enforcing ophthalmic patents against ANDA applicants.

Weaknesses

• The active ingredient was established and available from earlier products.
• The claimed formulation differences could invite obviousness challenges.
• Narrow concentration or excipient limitations can permit noninfringing alternatives.
• A generic applicant could pursue multiple ANDA strategies, including different strengths or formulations.
• The patent estate did not create biologic-style manufacturing exclusivity.

The estate was strongest as a regulatory and timing barrier. Its value was less certain as an absolute long-term exclusionary right because the underlying molecule was old and the formulation claims faced predictable obviousness and claim-construction attacks.

Which companies challenged Allergan's ophthalmic products?

Allergan faced generic challenges across several ophthalmic franchises. Applicants included Lupin, Sandoz, Apotex, Mylan and other generic manufacturers, depending on the product.

The competitive landscape included:

• Bimatoprost products competing with Lumigan.
• Brimonidine/timolol products competing with Combigan.
• Cyclosporine ophthalmic products competing with Restasis.
• Other glaucoma and ocular-inflammation products subject to formulation and method-of-use litigation.

Each product required a separate analysis because patent expiration, Orange Book listings, ANDA certifications, settlement terms and FDA approval dates were product-specific.

What generic launch risks existed for Lupin?

Lupin faced four principal risks:

1. Infringement risk. If its formulation met the asserted claim limitations, a judgment could block commercial launch.
2. Invalidity risk. A successful obviousness challenge could eliminate Allergan's principal barrier and accelerate competition.
3. Regulatory delay. The Paragraph IV case could delay final approval during the statutory stay.
4. Commercial substitution risk. Even after approval, Lupin would face established generic competition and possible authorized-generic entry.

Allergan faced the opposite risk: a finding that the formulation claims were invalid or not infringed could convert a protected branded product into an exposed generic market before the expected patent expiry.

Did the case involve biosimilars or manufacturing patents?

No. The dispute involved a small-molecule ophthalmic drug and an ANDA, not a biologic and a biosimilar application.

Manufacturing barriers were secondary. The important intellectual-property barrier was the finished ophthalmic formulation and its use in treating elevated intraocular pressure. Manufacturing know-how could affect product quality and FDA approval, but it was not the principal legal issue identified with this docket.

Key Takeaways

• Allergan v. Lupin, No. 2:11-cv-00530, was a Hatch-Waxman dispute over generic bimatoprost ophthalmic solution.
• The litigation was associated with Lumigan 0.01%, Allergan's lower-concentration bimatoprost product.
• U.S. Patent No. 7,851,504 was the principal later-generation formulation patent linked to the product.
• The case involved generic-entry risk, not biosimilar competition.
• Allergan's strongest protection came from the later formulation estate rather than the original bimatoprost molecule patent.
• The commercial impact depended on the validity, scope and expiration of the Orange Book-listed formulation patents, together with any settlement restrictions.
• Generic approval and launch required separate analysis by applicant, dosage strength, formulation and patent certification.

FAQs

What is the difference between Lumigan 0.01% and Lumigan 0.03%?

Lumigan 0.01% contains a lower concentration of bimatoprost than the original 0.03% product. Allergan used formulation and treatment patents to protect the later-generation product.

Is bimatoprost a biologic drug?

No. Bimatoprost is a small-molecule ophthalmic drug. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Does a Paragraph IV lawsuit automatically prevent FDA approval?

No. A Paragraph IV lawsuit can trigger a statutory stay of FDA approval, but the stay has a defined duration and can end earlier through judgment, settlement or other legal events.

Can a generic company avoid a formulation patent by changing excipients?

Possibly. A changed excipient profile may avoid infringement if the generic product does not satisfy the patent's claim limitations, but the alternative formulation must still meet FDA quality and bioequivalence requirements.

Why are ophthalmic formulation patents commercially important?

Ophthalmic products often depend on precise concentrations, preservatives, pH, viscosity and delivery characteristics. Those parameters can support later patent protection after the active ingredient's original patent term has substantially run.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
2. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,851,504: Ophthalmic compositions comprising bimatoprost. USPTO.
3. U.S. District Court for the District of Delaware. (2011). Allergan, Inc. v. Lupin Ltd., No. 2:11-cv-00530.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.